Animal Workstations Global Market Report 2023 – By Equipment (Dual Access Workstation, Bedding Disposal Workstation, Single-Sided Workstation, Universal Animal Containment Workstation), By Animal (Small Animals, Large Animals), By Technology (Vented Workstations, Anesthetic Workstations, Microscope Workstations, Other Technologies), By End User (Veterinary Hospitals and Clinics, Research Laboratories, Other End Users) – Market Size, Trends, And Global Forecast 2023-2032

Animal hospitals and veterinary clinics refer to a type of premises at which veterinary surgery is practiced but at which animals are not retained overnight, whereas in veterinary hospitals, veterinary surgery is practiced and animals receive treatment and nursing care, and other services include the reception, treatment, and care of animals suffering from disease or injury or in need of surgical or medical treatment or assistance. The main types of animal hospitals and veterinary clinics' services are consultation, surgery, medicine, and other types. Veterinary doctors perform the surgery to correct any medical issues that animals may have. The types of animals that avail themselves of these services include farm animals and companion animals that are used in animal care, animal rescue, and other end-users. The global animal hospitals and veterinary clinics market is segmented - 1) By Type: Consultation, Surgery, Medicine, Other Types 2) By Animal Type: Farm Animals, Companion Animals 3) By End User: Animal Care, Animal Rescue, Other End Users The global animal hospitals and veterinary clinics market size grew from $107.76 billion in 2022 to $117.13 billion in 2023 at a compound annual growth rate (CAGR) of 8.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global animal hospitals and veterinary clinics is expected to grow to $157.02 billion in 2027 at a CAGR of 7.6%. The rise in the adoption of companion pets globally is driving the animal hospitals and veterinary clinics market demand. The key factor behind this rise in adoption is the increasing humanization of pets, as an increasing number of pet owners are accepting pets as family members. According to the American Veterinary Medical Association report, there was a correlation between the degree of human-animal bond and pet spending. According to the American Society for the Prevention of Cruelty to Animals (ASPCA), in the USA, approximately 3.2 million shelter animals are adopted each year. Also, according to a study, Americans spent about $17 billion on veterinary care in hospitals, clinics, and food. Similarly, Chinese pet owners spent more than 5,000 yuan per pet. With this growth, the animal hospitals and veterinary clinics market is expected to grow in the forecast period. Major players in the animal hospitals and veterinary clinics market are VCA Inc., Banfield Pet Hospital, Greencross Ltd., CVS Group PLC., Mars, Inc., National Veterinary Care Ltd., Pets at Home Group PLC., Ethos Veterinary Health, Animart LLC., and The Bargh Memorial Animal Hospital ASPCA. Veterinary healthcare access is relatively poor in most developing countries and some developed nations. Globally, the disease burden is significantly high in low and middle-income countries. For instance, India reported approximately 63,000 veterinarians while the country required more than 150,000 veterinarians. Thus, the shortage of skilled veterinary professionals is harming the growth of the animal hospital and veterinary clinic market. Many veterinary care service providers are adopting big data technologies to provide better treatment for pets, livestock, and animals. This technology is used to diagnose and assess potential diseases. Big data enables veterinarians to identify the diseases affecting cattle and pets in various locations and regions. For instance, Bayer Healthcare Animal introduced applications to assess potential signs of diseases in animals, thus enabling faster diagnosis and treatment of disease conditions. Some of the major veterinary care providers opting for big data analytics to treat pet health issues are VCA Inc., Banfield Pet Hospitals, and Greencross Limited. The animal hospital and veterinary clinic market is regulated by authorities such as the Australian Pesticides and Veterinary Medicines Authority (APVMA). In Australia, Section 24A of the Veterinary Surgeons Act 1960, prescribes that premises that will be or are used as a veterinary clinic or veterinary hospital (veterinary premises) must be registered by the Veterinary Surgeons’ Board (Board). The Board only registers veterinary premises when it is satisfied that the premises are suitable for the purpose for which they are proposed to be used and the veterinary premises are under the management of a veterinary surgeon. North America was the largest region in the animal hospitals and veterinary clinics market in 2022. Asia-Pacific was the second-largest region in the global animal hospitals and veterinary clinics market share. The regions covered in the animal hospitals and veterinary clinics market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the animal hospitals and veterinary clinics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The animal hospitals and veterinary clinics market includes revenues earned by entities by providing diagnosis, treatment, and care to patients and offering preventive healthcare schedules to improve the health condition of pets and other animals. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The animal hospitals and veterinary clinics research report is one of a series of new reports from The Business Research Company that provides animal hospitals and veterinary clinics market statistics, including animal hospitals and veterinary clinics industry global market size, regional shares, competitors with animal hospitals and veterinary clinics market shares, detailed animal hospitals and veterinary clinics market segments, market trends and opportunities, and any further data you may need to thrive in the animal hospitals and veterinary clinics industry. This animal hospitals and veterinary clinics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Veterinary services refers to various tests conducted for diagnosis of infectious agents, toxins, and other causes of diseases in animals. The main technologies of veterinary laboratory testing services are clinical biochemistry, immunodiagnostics, hematology, molecular diagnostics, urinalysis, and other technologies. Clinical Biochemistry is the branch of laboratory medicine concerned with the detection of chemicals (both natural and synthetic) in blood, urine, and other bodily fluids. These veterinary laboratory testing services are beneficial for pet animals and livestock and are used by veterinary hospitals and clinics, diagnostic laboratories, research institutes, in-house testing, and other end users. The global veterinary laboratory testing services market is segmented - 1) By Technology: Clinical Biochemistry, Immunodiagnostics, Hematology, Molecular Diagnostics, Urinalysis, Other Technologies 2) By Animal Type: Pet Animals, Livestock 3) By End User: Veterinary Hospitals And Clinics, Diagnostic Laboratories, Research Institutes, In-House Testing, Other End Users The global veterinary laboratory testing services market size will grow from $23.39 billion in 2022 to $25.75 billion in 2023 at a compound annual growth rate (CAGR) of 10.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size veterinary laboratory testing services is expected to grow from $36.19 billion in 2027 at a CAGR of 8.9%. Major players in the veterinary laboratory testing market are ABAXIS, Inc., IDEXX Laboratories, Inc., Heska Corporation, Pfizer Animal Health, Neogen Corporation, Thermo Fisher Scientific Inc., Zoetis, Inc., IDVet, Virbac, Zoetis, VCA Antech, Inc., and Prionics AG. The veterinary laboratory testing services market is being driven by the rising prevalence of disease epidemics in animals. For instance, cattle are getting infected by a wide group of pathogens, which is leading to a rise in the number of laboratory tests done for cattle. Moreover, livestock globally is becoming vulnerable to infectious diseases caused by pathogens and viruses. For instance, Salmonella and Campylobacter are the two most common zoonotic pathogens that are present in the intestine tracts of animals, such as chickens, swine, and cattle, and are leading causes of foodborne disease worldwide. These diseases get passed through the food chain to humans, which is a potential threat. Therefore, efforts to curb these infections in animals are driving the market for veterinary laboratory testing. The FoodNet system (Center for Disease Control and Prevention, USA) identified 24,484 foodborne illnesses, 5,677 hospitalizations, and 122 deaths. The highest incidences per 100,000 people were for Campylobacter, Salmonella, and Shigella(these are organisms causing bacterial gastroenteritis, which is a digestive problem) in the USA. The veterinary laboratory testing services market is being restrained by a lack of animal healthcare awareness in emerging markets, which is responsible for causing many animal-related diseases to go untreated. Some of the ry laboratory testing services market is being restrained by a lack of animal healthcare awareness in emerging markets, which is responsible for causing many animal-related diseases to go untreated. Some of the illnesses in animals are often unknown or undiagnosed due to a lack of awareness. For instance, in emerging countries like India, China, and South Africa, diseases like rabies, which can be detected through veterinary testing, are often left undiagnosed, which results in the deaths of a large number of people who are bitten by rabid animals in these countries. For example, more than 55,000 people globally die of rabies every year, and around 30,000 of these cases are from India. According to Prof Andrew Leisewitz from the University of Pretoria, around 27,000 cases of animal rabies were reported, but the estimated number of actual cases was much higher. Such a lack of awareness, especially in emerging markets, is restraining the veterinary laboratory testing services market. The companies in the veterinary laboratory testing services are increasingly adopting multiple testing panels. A test panel is a pre-decided group of medical tests to be used in the diagnosis as well as the treatment of an animal disease. The test panels are normally composed of individual laboratory tests, which are grouped by specimen type, the methodology used, or by the most frequently requested tests. Multiple test panels offer various advantages, such as labour efficiency, automation, and reduced costs, achieved by conducting a large number of tests daily. For instance, Abaxis Inc. is using multiple single-use test panels designed to address several conditions, wherein just 3 to 4 drops of blood are required to deliver up to 14 precise results. The veterinary laboratory testing market in the US is subject to regulations by the Center for Disease Control and Prevention (CDC). The CDC requires the professionals responsible for conducting the tests to undergo technical training at the National Veterinary Services Laboratories (NVSL). The veterinary laboratory personnel are required to conduct the tests licenced by the United States Department of Agriculture(USDA) as per the label instructions or the official protocols provided by the NVSL. Further, the CDC requires the laboratory personnel to test only those samples submitted by accredited veterinarians and report the test results within 48 hours of completion. Laboratory inspections must be conducted by animal health officials periodically. In February 2020, Zoetis, Inc., a US-based animal health company specializing in the discovery, development, production, and marketing of animal health drugs, acquired Ethos Diagnostic Science for an undisclosed amount. Through this acquisition, Zoetis continues to expand its diagnostics presence in order to provide American veterinarians with comprehensive services at an improved value. Ethos Diagnostic Science is a US-based veterinary diagnostic company pioneering in various types of diagnostic testing and clinical chemistry. North America was the largest region in the veterinary laboratory testing market in 2022. Asia-Pacific was the second-largest region in the global veterinary laboratory testing market report. The regions covered in the global veterinary laboratory testing services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the veterinary laboratory testing services market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The veterinary laboratory testing services market consists of revenues earned by entities that use technologies such as clinical biochemistry, immunodiagnostics, hematology, molecular diagnostics, urinalysis, and others for the diagnosis of animal diseases. The tests conducted involve chemistry, pathology, serology, radiography and endocrinology related assessments. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The veterinary laboratory testing services research report is one of a series of new reports from The Business Research Company that provides veterinary laboratory testing services statistics, including veterinary laboratory testing services industry global market size, regional shares, competitors with veterinary laboratory testing services share, detailed veterinary laboratory testing services segments, market trends and opportunities, and any further data you may need to thrive in the veterinary laboratory testing services industry. This veterinary laboratory testing services research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

The non-animal alternatives testing is testing products and services that do not involve testing on animals to determine the safety and efficacy of products and ingredients used in any industry sector. Non-animal alternative testing technologies include: in-vitro human cell and tissue cultures; organs-on-chips (OOCs); computer simulations and modelling (silico models); 3D bio-printing of tissues; and synthetic skin substitutes; as well as studies with human volunteers. These technologies replace animal testing in end-use industries including pharmaceuticals, medical devices, chemicals and pesticides, food, and others. The non-animal alternatives testing market research report is one of a series of new reports from The Business Research Company that provides non-animal alternatives testing market statistics, including non-animal alternatives testing industry global market size, regional shares, competitors with a non-animal alternatives testing market share, detailed non-animal alternatives testing market segments, market trends and opportunities, and any further data you may need to thrive in the non-animal alternatives testing industry. This non-animal alternatives testing market research report provides a comprehensive view of everything you require, including an in-depth analysis of the industry's current and future scenario. The global non-animal alternatives testing market is segmented - 1) By Technology: Cell Culture Technology, High Throughput Technology, Molecular Imaging, Omics Technology, Other Technologies 2) By Method: Cellular Assay, Biochemical Assay, In Silico., Ex-vivo 3) By End-User: Pharmaceutical Industry, Cosmetics & Household Products, Diagnostics, Chemicals Industry, Food Industry The global non-animal alternatives testing market size grew from $1.78 billion in 2022 to $1.94 billion in 2023 at a compound annual growth rate (CAGR) of 9.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global non-animal alternatives testing is expected to grow from $2.9 billion in 2027 at a CAGR of 10.5%. The support from the government and non-governmental organizations boosts the growth of the non-animal testing market. The government organizations enforce laws and regulations, raise funds to support non-animal testing methods such as tests on human volunteers, and advanced computer-modeling techniques, and also fund studies with human volunteers. In order to support non-animal testing, People for the Ethical Treatment of Animals (PETA) India, in 2022, announced a grant of 7 lakh rupees in order to advance animal-free methods for toxicology testing. Similar research programs to promote non-animal testing procedures are also initiated by countries such as Denmark, Brazil, Germany, Switzerland, Australia, China, and Korea. The constant support from the government drives the growth of the non-animal testing market. Major players in the non-animal alternatives testing are MatTek Corporation, Cyprotex, Emulate Inc., BioIVT, Bio-Rad Laboratories, GE Healthcare, SGS SA, BioIVT, Abbott Laboratories and Gentronix Limited. Stringent regulations related to safety, efficacy, and quality are projected to act as a major challenge for players operating in the non-animal alternative testing market. All medicines and treatments go through stringent testing in the lab (pre-clinical research) and in small groups of patients (clinical research). The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) are the two main bodies regulating these novel therapies while getting them to market. Health Canada uses mAb specific guidelines from EMA or USFDA when necessary. The SAHPRA (South African Health Products Authority) biosimilar guideline has an annex on mAbs which focuses on non-clinical and clinical aspects. The Russian Federation has issued general product registration guidelines with very brief information about mAbs. Since it is a time-consuming process, it is considered one of the major hindering factors for the non-animal alternative testing market. OOCs (organs-on-chips) tool for testing is a major trend in the non-animal alternatives testing market. Organs-on-a-chips (OOCs) are miniature tissues and organs grown in-vitro that enable the modelling of human physiology and disease. OOCs are now being explored worldwide as tools for developing disease models and accurately predicting drug efficacies and toxicities. The advantages of OOCs over cell culture, animal models, and human clinical trials have captured the attention of both the medical and pharmaceutical communities, focusing on developing targeted therapies. For instance, in April 2020, researchers at the Massachusetts Institute of Technology (MIT) in the US developed a new model for Organs-on-a-Chip to develop treatments for inflammatory diseases and afflictions. Organs-on-a-chip consist of millions of cells formed on a platform to replicate the functions of different organs and can be used as an instrument in analysing and creating new treatments for complex diseases without the use of animals for testing. North America was the largest region in the non-animal alternatives testing in 2022. Western Europe was the second-largest region in the non-animal alternatives testing market report. The regions covered in the non-animal alternatives testing indutry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The non-animal alternatives testing market consists of revenue earned by that perform organs-on-chips (OOCs) technology, and 3D bio-printing of tissues among others. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for specified geography are consumption values – that is, they are revenues generated by organisations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales along the chain or as part of other products. The main methods of non-animal alternative testing are cellular assay, biochemical assay, in siliCo., and ex-vivo. A biochemical assay is an in vitro analytical process used to detect, quantify, and/or investigate the binding or activity of a biological molecule, such as an enzyme. The various technologies used include cell culture technology, high throughput technology, molecular imaging, omics technology, and other technologies. These are utilised by industries such as the pharmaceutical industry, cosmetics and household products, diagnostics, the chemical industry, and the food industry.

Companion animal vaccines are substances that are used to stimulate the production of antibodies and provide immunity against one or several diseases in pets such as dogs, birds, and cats. They are also used to improve food digestion, enhance immunity, enable animals to gain fat and weight, and generate good quality meat that is harvested for commercial purposes. The main products of companion animal veterinary vaccines are inactivated, live attenuated, recombinant, and other products. A recombinant vaccine is one that was created using recombinant DNA technology. This entails inserting DNA encoding an antigen (such as a bacterial surface protein) that triggers an immunological response into bacterial or mammalian cells, expressing the antigen in these cells, and then purifying it from them. The products are administered through oral, parenteral, and other routes of administration and are distributed through veterinary hospitals, veterinary clinics, pharmacies, drug stores, and other distribution channels. The global companion animal veterinary vaccines market is segmented - 1) By Product: Inactivated, Live Attenuated, Recombinant, Other Products 2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration 3) By Distribution Channel: Veterinary Hospitals, Veterinary Clinics, Pharmacies And Drug Stores, Other Distribution Channels The global companion animal veterinary vaccines market size will grow from $3.25 billion in 2022 to $3.47 billion in 2023 at a compound annual growth rate (CAGR) of 6.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global companion animal veterinary vaccines market size is expected to grow to $4.48 billion in 2027 at a CAGR of 6.6%. Increased pet ownership by Gen X and Gen Y adults contributed to the growth of the companion animal veterinary vaccine market during the historic period. According to the APPA, millennials, or Gen Y, represent the largest segment of pet owners for all types of pets. More than 80% of Gen Y and Gen Z own a dog, and 50% or less own a cat as a pet. Multiple pet ownership is also on the rise in some parts of the world. According to the 2019-2020 APPA National Pet Owners Survey, 67% of US households own pets, which is equal to 84.9 million homes. Pet owners are well aware of advanced facilities and are willing to spend a large amount of money on the health of their pets. Therefore, the rise in pet ownership aids in the growth of the companion animal veterinary vaccine market. Major players in the companion animal veterinary vaccines market are Boehringer Ingelheim, Eli Lilly and Company (Elcano), Heska Co., Merck Animal Health, Virbac, Zoetis, ElancoCevaSante Animal S.A., Bayer Healthcare, NEOGEN CORPORATION, and ImmuCell Corporation. The high cost of veterinary vaccines is expected to restrain the growth of the market. According to data from Harris Interactive, in the USA, households with pets spend about $1,000 on pet care. There are around 70% of households in the USA who own a pet and only 39% have enough in their savings to cover high spending related to pet care. According to a report by PET IQ, in the USA, nearly 28% of households experienced barriers to veterinary care in the past two years. 80% of pet owners are unable to obtain preventative care due to financial constraints. There are several instances when it happens that the pet owners cannot afford expensive animal treatment and this factor restrained the growth of the companion animal veterinary vaccines market. Usually, the average cost of the rabies vaccine varies, typically from about $1,200 to $6,500. Thus, the high cost of companion animal veterinary vaccines will restrain the growth of the market over the forecast period. Companies in the companion animal veterinary vaccine industry are increasingly collaborating and partnering with other players to drive product innovations. To succeed in the increasingly competitive veterinary market, companion animal veterinary vaccine companies are entering into new geographies and developing innovative products through sharing skills and expertise with other players. For instance, Merck & Co.’s subsidiary MSD Animal Health announced a strategic partnership with Vinovo B.V., a division of Viscon Hatchery Automation, the leading hatchery automation company, to provide a new standard in safe and effective Vinovo vaccination to improve bird welfare and reduce vaccine reactions. In February 2020, Zoetis, Inc., a US-based animal health company specializing in the discovery, development, production, and marketing of animal health drugs, acquired Ethos Diagnostic Science for an undisclosed amount. Through this acquisition, Zoetis continues to expand its diagnostics presence in order to provide American veterinarians with comprehensive services at an improved value. Ethos Diagnostic Science is a US-based veterinary diagnostic company pioneering in various types of diagnostic testing and clinical chemistry. North America was the largest region in the companion animal veterinary vaccines market share in 2022. Asia-Pacific was the second-largest region in the global companion animal veterinary vaccines market. The regions covered in the global companion animal veterinary vaccines market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the companion animal veterinary vaccines market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The companion animal veterinary vaccine market consists of sales of toxoid vaccines, viral vector vaccines, messenger RNA vaccines, and conjugated vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The companion animal veterinary vaccines research report is one of a series of new reports from The Business Research Company that provides companion animal veterinary vaccines statistics, including companion animal veterinary vaccines industry global market size, regional shares, competitors with companion animal veterinary vaccines share, detailed companion animal veterinary vaccines segments, market trends and opportunities, and any further data you may need to thrive in the companion animal veterinary vaccines industry. This companion animal veterinary vaccines research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Veterinary services refer to a type of service that is engaged in providing veterinary services to pets, farm animals, and animals kept in zoos and wildlife parks, including animal hospitals and veterinary clinics that provide consultation services, treatment, and curative medicines to animals to improve their health and life cycles. The main types of veterinary services are animal hospitals and veterinary clinics, and veterinary laboratory testing services. Veterinary laboratory testing services refer to the services that are provided to animals to test for a disease. The types of services offered are onsite and offsite and are used for livestock and companion animals. The expenditure includes public and private. The global veterinary services market is segmented - 1) By Type: Animal Hospitals And Veterinary Clinics, Veterinary Laboratory Testing Services 2) By Type of Animal: Livestock, Companion Animals 3) By Type of Expenditure: Public, Private 4) By Type of Service: Onsite, Offsite Subsegments Covered: Routine Examinations, Non-surgical Procedures, Surgical Procedures, Pet Animals Laboratory Testing Services, Livestock Laboratory Testing Services The global veterinary services market size will grow from $131.15 billion in 2022 to $142.88 billion in 2023 at a compound annual growth rate (CAGR) of 8.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, and affecting many markets across the globe. The market size of veterinary services is expected to grow from $193.21 billion in 2027 at a CAGR of 7.8%. Global meat production is expected to rise in the forecast period, supporting the growth of the veterinary healthcare market. According to the US Department of Agriculture, in 2020, beef production in the USA increased to 27.5 billion pounds, the highest production volume registered in the country. Rising meat production is especially prominent in developing countries such as China, India, and Brazil, where increasing populations and rising income levels are stimulating the demand for meat products. By 2027, the production of meat and poultry in emerging markets is expected to increase by 76%. By 2050, China's meat imports are expected to grow by over 3,500% to $150 billion as consumption of chicken, pork, and beef will surge due to the country's rising middle class. The rising production of meat products supported by the growing population will increase the demand for feed additives in the livestock industry, driving the veterinary healthcare market. Major companies in the veterinary services market include IDEXX Laboratories, Pets at Home Group PLC, National Veterinary Associates, Greencross Limited, Qiagen N.V., CVS Group Plc, The Animal Medical Center, Dechra Pharmaceuticals, and Neogen Corporation. The outbreak of COVID-19 disease (COVID-19) has acted as a massive restraint on the veterinary services market in 2020 as supply chains were disrupted due to trade restrictions and consumption declined due to lockdowns imposed by governments globally. COVID-19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty breathing. The virus was first identified in 2019 in Wuhan, Hubei province of the People’s Republic of China, and has spread globally, including Western Europe, North America, and Asia. Steps by national governments to contain the transmission have resulted in a decline in economic activity with countries entering a state of ""lock down"" and the outbreak hurting businesses throughout 2020 and into 2021. However, it is expected that the veterinary services market will recover from the shock across the forecast period as it is a ""black swan"" event and not related to ongoing or fundamental weaknesses in the market or the global economy. Telemedicine is gaining traction as this technology enables pet owners to get access to quality care from remote locations. Telemedicine is a subset of telehealth that includes remote clinical and non-clinical elements of the healthcare system. It refers to the direct communication between veterinarians and clients via communication systems such as phones, mail, and video conferencing technologies. This technology also helps in improving existing veterinarian-client-patient relationships. Busy lifestyles and consumers' preference for personalised services are driving the demand for telemedicine services. For instance, some of the veterinary clinics offering telemedicine include Televet, Fuzzy Pet Health, and Healthpets. North America was the largest region in the veterinary services market in 2022. Asia-Pacific was the second-largest region in the veterinary services market share. The regions covered in the veterinary services report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the veterinary services market include Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The veterinary services market includes revenues earned by entities by providing treatment for ill animals, prevention of production-limiting conditions, distribution of medicines, vaccinations, and other products.The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The veterinary services research report is one of a series of new reports from The Business Research Company that provides veterinary services statistics, including veterinary services industry global market size, regional shares, competitors with veterinary services share, detailed veterinary services segments, market trends and opportunities, and any further data you may need to thrive in the veterinary services industry. This veterinary services research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Small animal imaging (in-vivo) refers to the advanced imaging techniques for monitoring cellular activity, pharmacological effects that have been developed, and disease progression in live animals. The small animal imaging (in-vivo) is used to observe, define, and quantify normal and pathologic processes in living animal organs and tissues non-invasively. The main components of small animal imaging (in-vivo) are micro-MRI, optical imaging, nuclear imaging, and other components. Micro-MRI refers to a non-invasive technique that produces detailed 3-dimensional (3D) images of tissues without the use of harmful radiation. The various applications include monitoring treatment response, biodistribution, determining drug/target engagement, cancer cell detection, biomarkers, longitudinal studies, and epigenetics which are used in veterinary clinics, veterinary hospitals, and veterinary institutes and research centers. The global small animal imaging in vivo market is segmented – 1) By Component: Micro-MRI, Optical Imaging, Nuclear Imaging, Other Components 2) By Application: Monitoring Treatment Response, Bio Distribution, Determining Drug or Target Engagement, Cancer Cell Detection, Biomarkers, Longitudinal Studies, Epigenetics 3) By End User: Veterinary Clinics, Veterinary Hospitals, Veterinary Institutes and Research Centers The global small animal imaging (in-vivo) market size grew from $2.28 billion in 2022 to $2.54 billion in 2023 at a compound annual growth rate (CAGR) of 11.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global small animal imaging (in-vivo) is expected to grow to $3.8 billion in 2027 at a CAGR of 10.6%. Growing expenditure for the healthcare sector is expected to propel the growth of the small animal imaging (in-vivo) market going forward. Healthcare expenditure refers to the overall cost of health care (including public and private expenditures) as a percentage of GDP. Rising healthcare expenditure and increasing healthcare awareness, encourage the concept of self-care management where PET equipment is used in techniques such as small animal imaging. For instance, according to data released by the Organisation for Economic Co-operation and Development, a France-based intergovernmental economic organization, in 2020 health spending as a share of GDP jumped to 9.7% across OECD countries, up from 8.8% in 2019. A group of 17 OECD countries suggests that health spending continued to grow strongly in 2021 by around 6%. Therefore, growing expenditure for the healthcare sector is driving the growth of the small animal imaging (in-vivo) market. Major players in the market are Bruker, PerkinElmer, Miltenyi Biotec, Aspect Imaging Ltd., Mediso Ltd., LI-COR Biosciences, Life Technologies Corporation, Trifoil Imaging, Promega Corporation, New England Biolabs, MR Solutions Ltd., General Electric, Sofie Biosciences Inc., Biospace Lab, and Agilent Technologies Inc. Technological advancement is a key trend gaining popularity in the small animal imaging (in-vivo) market. Major companies operating in the small animal imaging (in vivo) market are focused on technological advancement to strengthen their position. For instance, in April 2022, PerkinElmer, Inc., a US-based company engaged in business areas such as diagnostics, life science research, and imaging, launched the Vega imaging system, an automated advanced technology ultrasound platform. The automated technology involves the use of two automated transducers, resulting in easy-to-use technology and generating more consistent results to visualize the pathophysiology of the disease. In August 2021, Rigaku Corporation, a Japan-based global manufacturer and distributor of scientific and industrial instrumentation primarily in X-ray and imaging technologies, acquired MILabs B.V. for an undisclosed amount. With this acquisition, Rigaku enlarged its global life sciences modality business by merging its original X-ray imaging business with MILabs' multi-modality businesses for animals, which included PET (Positron Emission Tomography), SPECT (Single Photon Emission Computed Tomography), Optical Imaging, and CT (Computed Tomography) equipment. MILabs B.V. is a Netherland-based company engaged in the development and manufacturing of molecular preclinical imaging systems such as SPECT, PET, CT, and optical imaging systems operating in small animal imaging(in-vivo). North America was the largest region in the small animal imaging (in-vivo) market in 2022. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in small animal imaging (in-vivo) market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the small animal imaging (in-vivo) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The small animal imaging (in-vivo) market includes revenues earned byPET, X-ray CT, MRI, and SPECT scanners. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The small animal imaging(in-vivo)market research report is one of a series of new reports from The Business Research Company that provides small animal imaging(in-vivo)market statistics, including small animal imaging(in-vivo)industry global market size, regional shares, competitors with a small animal imaging(in-vivo)market share, detailed small animal imaging(in-vivo)market segments, market trends and opportunities, and any further data you may need to thrive in the small animal imaging(in-vivo)industry. This small animal imaging(in-vivo)market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Animal medicines refer to a collective term for drugs and therapies, including veterinary vaccines, veterinary antibiotics, and other veterinary pharmaceuticals, that are used to treat animal diseases to improve animals’ performance and health by identifying disease symptoms and drugs for the cure of illness. The main types of animal medicines are veterinary pharmaceuticals and feed additives, which are used for livestock and companion animals. Veterinary pharmaceuticals refer to animal medicine that is given to animals for treating diseases. Animal medicine is used by veterinary hospitals, pharmacies, drug stores, and veterinary clinics. The global animal medicine market is segmented - 1) By Type: Veterinary Pharmaceuticals, Feed Additives 2) By Type of Animal: Livestock, Companion Animals 3) By End-Use: Veterinary Hospitals, Pharmacies And Drug Stores, Veterinary Clinics Subsegments Covered: Veterinary Vaccines, Veterinary Antibiotics, Veterinary Parasiticides, Other Veterinary Pharmaceuticals, Medical Feed Additives, Nutritional Feed Additives The global animal medicine market size will grow from $46.91 billion in 2022 to $50.47 billion in 2023 at a compound annual growth rate (CAGR) of 7.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, and affecting many markets across the globe. The market size of animal medicine is expected to grow from $65.12 billion in 2027 at a CAGR of 6.6%. The increasing penetration of pet insurance is expected to drive the animal medicine market. Globally, the pet insurance market is largely untapped with extremely low penetration rates, providing a large market opportunity. In developed economies such as the USA, the pet insurance penetration rate is around 1%, although in Western European countries such as the UK, the penetration rate is around 20%. During the forecast period, the pet insurance market in the USA is expected to grow by $2 billion in 2022, at a compound annual growth rate of 14%, mainly driven by the increasing consumer awareness and rising disposable income of companion animal owners. Increasing penetration of pet insurance will increase the number of visits at veterinary clinics supporting the use of animal medicine in the treatment of different diseases. Major companies in the animal medicine market include Zoetis Inc., Boehringer Ingelheim GmbH, Merck & Co, Evonik Industries AG, Patterson Companies Inc., Ceva Animal Health LLC – Biomune, Phirbo Animal Health, Dechra Pharmaceuticals, Virbac Group, and Vetoquinol S.A. The outbreak of COVID-19 disease (COVID-19) has acted as a massive restraint on the animal medicine market in 2020 as supply chains were disrupted due to trade restrictions and consumption declined due to lockdowns imposed by governments globally. COVID-19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty breathing. The virus was first identified in 2019 in Wuhan, Hubei province of the People’s Republic of China, and has spread globally, including Western Europe, North America, and Asia. Steps by national governments to contain the transmission have resulted in a decline in economic activity with countries entering a state of "lock down" and the outbreak hurting businesses throughout 2020 and into 2021. However, it is expected that the animal medicine market will recover from the shock over the forecast period as it is a "black swan" event and not related to ongoing or fundamental weaknesses in the market or the global economy. Nanotechnology is increasingly gaining traction in the animal medicine market as a substitute for veterinary antibiotics. Nanotechnology is the study of controlling matter on an atomic and molecular scale. In the animal medicine industry, nanotechnology is used to improve diagnosis, treatment, animal growth promotion, and production. Nanoparticles are mainly used as alternative antimicrobial agents to reduce the use of antibiotics and improve the detection of pathogenic bacteria. They are also used as drug delivery agents for new drugs and vaccine candidates to improve their characteristics and performance and to reduce drug resistance in animal organisms. North America was the largest region in animal medicine market in 2022. Asia-Pacific was the second-largest region in the animal medicine market analysis. The regions covered in the animal medicine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the animal medicine market include Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The animal medicine market consists of sales of procuring drugs to shield against external parasites like fleas, ticks, and heartworms (intestinal parasites). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The animal medicine research report is one of a series of new reports from The Business Research Company that provides animal medicine statistics, including animal medicine industry global market size, regional shares, competitors with animal medicine shares, detailed animal medicine segments, market trends and opportunities, and any further data you may need to thrive in the animal medicine industry. This animal medicine research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The animal antibiotics and antimicrobials refer to veterinary medications that work against bacteria or microorganisms by either killing bacteria/microorganisms or limiting their development and multiplication. These medications are used in animals to treat clinical diseases, to prevent or control common disease events, and enhance animal growth. The main types of animal antibiotics and antimicrobials include tetracyclines, penicillins, sulfonamides, macrolides, aminoglycosides, lincosamides, fluoroquinolones, cephalosporins, and other antimicrobials and antibiotics. Tetracyclines are bacteriostatic, and their mechanism of action is through reversible binding of bacterial 30S ribosomes and alteration of bacterial cytoplasmic membrane. They are also referred to as oral medication used in treatment of bacterial infections due to aerobic, gram-negative bacteria, mycoplasma, and others. These are delivered in different forms including premixes, oral powder, oral solutions, injection, and others. These medications are used in both companion and food-producing animals. The global animal antibiotics and antimicrobials market is segmented – 1) By Type of Product: Tetracyclines, Penicillins, Sulfonamides, Macrolides, Aminoglycosides, Lincosamides, Fluoroquinolones, Cephalosporins, Other Antimicrobials and Antibiotics 2) By Mode of Delivery: Premixes, Oral Powder, Oral Solution, Injection, Other Modes of Delivery 3) By Animal Type: Food-Producing Animals, Companion Animals The global animal antibiotics and antimicrobials market size will grow from $4.68 billion in 2022 to $5.07 billion in 2023 at a compound annual growth rate (CAGR) of 8.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of animal antibiotics and antimicrobials market is expected to grow to $6.95 billion in 2027 at a CAGR of 8.2%. Rising demand for animal-derived food products is driving the growth of the animal antibiotics and antimicrobials market. Animal-derived food products such as milk, eggs, meat, and other act a major source of nutrition and plays a prominent role in human diet. The companies/institutions involved in production of animal-derived foods are focusing on developing healthy herd or disease-free herd through utilization of animal antibiotics and antimicrobials on precautionary basis. According to the data published in the Packaged Facts report on Global Meat & Poultry trends, global meat and poultry consumption is expected to reach 313 million metric tons in 2023, at a year-on-year growth rate of 1.4%. Therefore, increasing demand for animal-derived food products is expected to boost demand for animal antibiotics and antimicrobials during forecast period. Major players in the animal antibiotics and antimicrobials market are Boehringer Ingelheim, Zoetis Inc., Elanco Animal Health, Merck & Co. Inc., Phibro Animal Health, Vetoquinol SA, Lutim Pharma, Ceva Santé Animale, Dechra Pharmaceuticals PLC., Kyoritsu Seiyaku, Huvepharma Inc., Zydus, Indian Immunologicals Pvt. Ltd., Bayer Animal Health, Virbac Animal Health, and Phibro Animal Health Corp. Strategic partnership is a key trend gaining popularity in the animal antibiotics and antimicrobials market. The companies operating in animal antibiotics and antimicrobial sector are entering into strategic partnerships with relevant industry players for the research and development of innovative animal antibiotics and antimicrobials. In May 2022, Gnubiotics Sciences, a Switzerland-based biotech company working to solve microbiome-related health conditions in humans and animals, entered into a partnership with ADM, a US-based developer of human and health nutrition solutions, for commercializing new microbiome solutions for companion animal health and wellbeing. In August 2020, Elanco, a US-based pharmaceutical company that manufacturers medicines and vaccinations for pets and livestock, acquired Bayer’s animal health business unit for $6.89 billion. With this acquisition, Elanco will improve its research and development pipeline and broaden its range of animal health products. Bayer’s animal health business unit is a Germany-based pharmaceutical and life sciences company. North America was the largest region in the animal antibiotics and antimicrobials market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the animal antibiotics and antimicrobials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the animal antibiotics and antimicrobials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The animal antibiotics and antimicrobials market consists of sales of glycopeptides, ß-Lactam antibiotics, and polymixins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The animal antibiotics and antimicrobials market research report is one of a series of new reports from The Business Research Company that provides animal antibiotics and antimicrobials market statistics, including animal antibiotics and antimicrobials industry global market size, regional shares, competitors with a animal antibiotics and antimicrobials market share, detailed animal antibiotics and antimicrobials market segments, market trends and opportunities, and any further data you may need to thrive in the animal antibiotics and antimicrobials industry. This animal antibiotics and antimicrobials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.